Clinical Trial Update: A Study of WR 6026 in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update for WR 6026 in Pneumocystis jirovecii pneumonia (PCP) among HIV-infected patients has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections
• Pneumocystis Pneumonia

Drugs mentioned

• WR 6026 (WR 6026)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections | Phase 2 | Status: COMPLETED